It should also be noted that a threshold of A1c ≥ 8% was selected for the present registry study to include only patients who would be candidates for insulin therapy, whereas people with an A1c of 7–8% are more likely to achieve their therapeutic goal with current therapy as an initial step, before adding a new treatment such as insulin.15 Accordingly, the characteristics of the patients included in the present study, being an incomplete cross-section of patients with T2DM, do not fully reflect the heterogeneity of the patient population. The gene discussed is INS; the disease is type 2 diabetes mellitus.